VIROGENETICS 
NYVAC-RG (vP879) is a recombinant rabies vaccine containing the rabies 
glycoprotein G gene. This vaccine is being proliferated for clinical testing in 
humans, and an IND application is being prepared for submission to the FDA 
(Appendix Q). 
The USD A/ APHIS has assigned Biosafety Level- 1 to a contained release 
involving a NYV AC-based Japanese Encephalitis Virus vaccine (vP908) to be 
administered to 150 swine at Purdue University (Appendix R). 
5. Geographical distribution: The NY VAC (vP866) vector has demonstrated 
the potential to be used as a vaccine for a wide variety of human and 
veterinary diseases worldwide. The highly attenuated phenotype of the 
NYV AC vector, coupled with its potency as an immunization vehicle provides 
a favorable benefit- to-risk ratio. It possesses the advantages of classical 
vaccinia-based vaccine candidates, yet has attenuation characteristics consistent 
with an enhanced safety profile. 
6, Recommended NIH/CDC Biosafety Level: The NIH/CDC recommended 
Biosafety Level for vaccinia is BL-2. Due to the highly attenuated nature of 
NYV AC, the absence of animal-to-animal transmission, and the demonstration 
of significantly limited replicative ability in human cells, we are requesting 
reduction to Biosafety Level 1. 
[172] 
Recombinant DNA Research, Volume 18 
